Anti-PD-1 monoclonal antibody

Phase 3Small molecule

Anti-PD-1 monoclonal antibody is one of 340 small molecule programs targeting Central Nervous System Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

339

Competitors

Pipeline

Status by Indication[3][1]

Indication

Central Nervous System LymphomaActive, not recruiting

LymphomaActive, not recruiting

Gastric AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

MelanomaActive, not recruiting

Pancreatic CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Central Nervous System LymphomaPhase 1/Phase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Gastric AdenocarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Anti-PD-1 monoclonal antibody

IiTeos Therapeutics

Phase 3

1 2

Tecentriq

Roche

Preclinical

36 3

Zolymbus

AbbVie

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Zinecard

CChildren's Oncology Group

Preclinical

2 6

Avastin

Roche

Preclinical

4 7

Nubain

AAultman Health Foundation

Preclinical

1 8

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 9

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 10

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Renal Cell Carcinoma

NCT06255223

Q4 2026

Phase 1/2Recruiting

Advanced Solid Tumors

NCT06425926

Phase 1/2Recruiting

Advanced Solid Tumor

NCT06603844

Phase 1/2Recruiting

Locally Advanced/metastatic Solid Tumors

NCT05699811

Phase 2Active, not recruiting

Immunotherapy

NCT05522582

Q2 2027

Phase 1/2Recruiting

Advanced Solid Tumors

NCT05941507

Clinical

Trials by Indication[1]

Advanced Solid Tumors4 trials

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

Active, not recruiting·IiTeos Therapeutics·Phase 1·NCT06547957·55 enrolled

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Recruiting·LLigaChem Biosciences, Inc.·Phase 1/2·NCT05941507·300 enrolled

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Recruiting·GGeorgiamune Inc·Phase 1/2·NCT06425926·117 enrolled

Show 1 more trial

Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Unknown status·TTaizhou Hanzhong biomedical co. LTD·Phase 2·NCT03704246·123 enrolled

Hepatocellular Carcinoma3 trials

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting·ZZe-yang Ding, MD··NCT05713994·300 enrolled

Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling

Completed·CChen Xiaoping··NCT06298123·304 enrolled

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Recruiting·TTongji Hospital··NCT05717738·300 enrolled

Immunotherapy3 trials

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

Active, not recruiting·—·Phase 2·NCT05522582·50 enrolled

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Recruiting·—·Phase 2·NCT06170710·173 enrolled

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

Recruiting·FFudan University·Phase 2·NCT06121700·55 enrolled

Lymphoma2 trials

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05182957·40 enrolled

Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 2·NCT04096690·22 enrolled

Pancreatic Cancer2 trials

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Recruiting·—·Phase 1/2·NCT04146298·30 enrolled

Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

Completed·ZZhejiang University·Phase 2·NCT03983057·392 enrolled

17 more indications

Anti-PD-1 Antibody2 trials

Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL

Unknown status·SSun Yat-sen University·Phase 2·NCT04676789·30 enrolled

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT05254899·54 enrolled

Renal Cell Carcinoma1 trial

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Recruiting·JJinling Hospital, China·Phase 2·NCT06255223·35 enrolled

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1/2·NCT07365592·138 enrolled

Non-Small Cell Lung Cancer1 trial

Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer

Recruiting·EEnergenx Medical LTD.·N/A·NCT05987345·10 enrolled

Radiotherapy1 trial

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT05149170·30 enrolled

Neoadjuvant Treatment1 trial

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05556200·58 enrolled

Locally Advanced/Metastatic Solid Tumors1 trial

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Recruiting·—·Phase 1/2·NCT05699811·40 enrolled

Soft Tissue Sarcoma1 trial

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma

Recruiting·FFudan University·Phase 1/2·NCT05774275·52 enrolled

Breast Cancer1 trial

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 3·NCT05429684·120 enrolled

Chemotherapy1 trial

Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05307198·38 enrolled

Melanoma1 trial

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy

Unknown status·—·Phase 2·NCT04928365·50 enrolled

Gastric Adenocarcinoma1 trial

Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma

Suspended·FFudan University·Phase 2·NCT06728657·68 enrolled

Central Nervous System Lymphoma1 trial

A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1/2·NCT06556199·38 enrolled

Stereotactic Body Radiotherapy1 trial

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Recruiting·ZZhejiang Cancer Hospital·N/A·NCT06349044·120 enrolled

Colorectal Cancer1 trial

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Unknown status·SShanghai Celfuture Biotech Co., Ltd.·Phase 2·NCT05684211·84 enrolled

Recurrent1 trial

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT07090148·14 enrolled

Advanced Solid Tumor1 trial

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Recruiting·CCorbus Pharmaceuticals Inc.·Phase 1/2·NCT06603844·156 enrolled

Sources

References

[1]
ClinicalTrials.gov — 32 trial records for Anti-PD-1 monoclonal antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-PD-1 monoclonal antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-PD-1 monoclonal antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — iTeos Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IiTeos Therapeutics

Anti-PD-1 monoclonal antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Trials by Indication[1]

Advanced Solid Tumors4 trials

Hepatocellular Carcinoma3 trials

Immunotherapy3 trials

Lymphoma2 trials

Pancreatic Cancer2 trials

Anti-PD-1 Antibody2 trials

Renal Cell Carcinoma1 trial

Neoadjuvant Chemotherapy1 trial

Non-Small Cell Lung Cancer1 trial

Radiotherapy1 trial

Neoadjuvant Treatment1 trial

Locally Advanced/Metastatic Solid Tumors1 trial

Soft Tissue Sarcoma1 trial

Breast Cancer1 trial

Chemotherapy1 trial

Melanoma1 trial

Gastric Adenocarcinoma1 trial

Central Nervous System Lymphoma1 trial

Stereotactic Body Radiotherapy1 trial

Colorectal Cancer1 trial

Recurrent1 trial

Advanced Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News